ProMeris

RSS

Withdrawn

This medicine's authorisation has been withdrawn

metaflumizone
MedicineVeterinaryWithdrawn

Spanish is available via eTranslation, the European Commission's machine translation service.

Translate to Spanish | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for ProMeris has been withdrawn at the request of the marketing authorisation holder.

български (BG) (217.29 KB - PDF)

Ver

español (ES) (192.56 KB - PDF)

Ver

čeština (CS) (217.67 KB - PDF)

Ver

dansk (DA) (191.94 KB - PDF)

Ver

Deutsch (DE) (193.36 KB - PDF)

Ver

eesti (ET) (191.37 KB - PDF)

Ver

ελληνικά (EL) (219.08 KB - PDF)

Ver

français (FR) (193.21 KB - PDF)

Ver

italiano (IT) (191.59 KB - PDF)

Ver

latviešu (LV) (213.28 KB - PDF)

Ver

lietuvių (LT) (214.74 KB - PDF)

Ver

magyar (HU) (212.15 KB - PDF)

Ver

Malti (MT) (218.75 KB - PDF)

Ver

Nederlands (NL) (191.68 KB - PDF)

Ver

polski (PL) (216.46 KB - PDF)

Ver

português (PT) (192.4 KB - PDF)

Ver

română (RO) (214.2 KB - PDF)

Ver

slovenčina (SK) (215.86 KB - PDF)

Ver

slovenščina (SL) (208.53 KB - PDF)

Ver

suomi (FI) (191.92 KB - PDF)

Ver

svenska (SV) (191.72 KB - PDF)

Ver

Product information

български (BG) (389.52 KB - PDF)

Ver

español (ES) (328.73 KB - PDF)

Ver

čeština (CS) (374.1 KB - PDF)

Ver

dansk (DA) (330.12 KB - PDF)

Ver

Deutsch (DE) (340.98 KB - PDF)

Ver

eesti (ET) (336.16 KB - PDF)

Ver

ελληνικά (EL) (400.6 KB - PDF)

Ver

français (FR) (342.69 KB - PDF)

Ver

italiano (IT) (310.69 KB - PDF)

Ver

latviešu (LV) (368.86 KB - PDF)

Ver

lietuvių (LT) (376.46 KB - PDF)

Ver

magyar (HU) (368.57 KB - PDF)

Ver

Malti (MT) (376.05 KB - PDF)

Ver

Nederlands (NL) (331.24 KB - PDF)

Ver

polski (PL) (391.6 KB - PDF)

Ver

português (PT) (331.45 KB - PDF)

Ver

română (RO) (368.38 KB - PDF)

Ver

slovenčina (SK) (386.11 KB - PDF)

Ver

slovenščina (SL) (371.43 KB - PDF)

Ver

suomi (FI) (337.57 KB - PDF)

Ver

svenska (SV) (330.13 KB - PDF)

Ver

Íslenska (IS) (332.3 KB - PDF)

Ver

norsk (NO) (340.4 KB - PDF)

Ver
Latest procedure affecting product information:IB/0012
08/07/2015

български (BG) (190.37 KB - PDF)

Ver

español (ES) (144.19 KB - PDF)

Ver

čeština (CS) (184.81 KB - PDF)

Ver

dansk (DA) (144.38 KB - PDF)

Ver

Deutsch (DE) (146.91 KB - PDF)

Ver

eesti (ET) (144.06 KB - PDF)

Ver

ελληνικά (EL) (186.84 KB - PDF)

Ver

français (FR) (141.5 KB - PDF)

Ver

italiano (IT) (144.6 KB - PDF)

Ver

latviešu (LV) (189.21 KB - PDF)

Ver

lietuvių (LT) (179.82 KB - PDF)

Ver

magyar (HU) (175.56 KB - PDF)

Ver

Malti (MT) (198.96 KB - PDF)

Ver

Nederlands (NL) (141.54 KB - PDF)

Ver

polski (PL) (163.63 KB - PDF)

Ver

português (PT) (144.35 KB - PDF)

Ver

română (RO) (142.48 KB - PDF)

Ver

slovenčina (SK) (181.1 KB - PDF)

Ver

slovenščina (SL) (174.66 KB - PDF)

Ver

suomi (FI) (144.95 KB - PDF)

Ver

svenska (SV) (141.76 KB - PDF)

Ver

Íslenska (IS) (141.82 KB - PDF)

Ver

norsk (NO) (141.71 KB - PDF)

Ver

Product details

Name of medicine
ProMeris
Active substance
metaflumizone
International non-proprietary name (INN) or common name
metaflumizone
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) code
QP53AX25

Pharmacotherapeutic group

Ectoparasiticides for topical use, incl. insecticides

Therapeutic indication

Treatment and prevention of flea infestations (Ctenocephalides canis and C. felis) in cats. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

Authorisation details

EMA product number
EMEA/V/C/000107
Marketing authorisation holder
Pfizer Limited 

Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom

Marketing authorisation issued
19/12/2006
Revision
8

Assessment history

This page was last updated on

Share this page